Spravato Insurance Coverage in Missouri in 2026
Spravato Insurance Coverage in Missouri in 2026
For Missouri residents considering Spravato (esketamine) for treatment-resistant depression, the practical question of insurance coverage often arises early. Spravato is the only FDA-approved ketamine-derived treatment for treatment-resistant depression, which gives it a reimbursement pathway that IV ketamine infusions lack. But coverage is not automatic — it requires documentation, prior authorization, and sometimes persistence. This post walks through how Missouri’s major payers handle Spravato in 2026.
Why Spravato Has a Coverage Pathway
When the FDA approved Spravato in 2019, it triggered the standard process by which commercial insurers and Medicaid programs develop coverage policies for new drugs. Because Spravato is indicated for a specific, well-defined condition — treatment-resistant depression (ICD-10: F33.2), broadly defined as inadequate response to at least two antidepressant trials — insurers have a clinical framework for evaluating prior authorization requests.
The FDA’s REMS program adds a layer of complexity. Spravato cannot be dispensed for home use. Every dose must be administered in a certified healthcare setting, with the patient self-administering under supervision and remaining for at least two hours of post-dose monitoring. This means the billing involves both a drug component and an administration/monitoring component — and both may require insurance authorization.
By contrast, IV ketamine infusions are off-label for psychiatric use and are not covered by any Missouri commercial insurer or by MO HealthNet on a routine basis. Patients pursuing IV ketamine should expect to pay out of pocket.
MO HealthNet Coverage for Spravato
MO HealthNet, Missouri’s Medicaid program, covers Spravato for eligible enrollees who meet clinical criteria. Missouri expanded Medicaid under the Affordable Care Act in August 2021, bringing hundreds of thousands of additional Missourians into MO HealthNet eligibility. This expansion has made Spravato a realistic option for a larger proportion of the state’s low-income population than was previously the case.
MO HealthNet operates through both fee-for-service and managed care arrangements. Missouri HealthNet managed care plans — currently including Centene and UnitedHealthcare Community Plan operating in Missouri — each have their own prior authorization processes and formulary management. The fee-for-service population has different billing rules.
To access Spravato through MO HealthNet:
- Confirm your plan type — are you in fee-for-service MO HealthNet or a managed care plan? Contact MO HealthNet member services if you are unsure.
- Get a psychiatric evaluation and diagnosis — your prescribing clinician must document the clinical basis for treatment (typically F33.2) and your history of prior antidepressant trials.
- Document step therapy — MO HealthNet plans generally require evidence that you have tried at least two antidepressants without adequate response. Have your medication history ready.
- Submit a prior authorization request — your prescribing clinician’s office submits clinical documentation to MO HealthNet or your managed care plan.
- Understand your appeal rights — if denied, Missouri Medicaid enrollees can request a state fair hearing through the Missouri Department of Social Services, Family Support Division.
For federal guidance on Medicaid drug coverage and patient rights, the Centers for Medicare and Medicaid Services publishes state Medicaid plan information.
Anthem Blue Cross Blue Shield of Missouri
Anthem Blue Cross Blue Shield of Missouri is a major commercial insurer in the state, covering employer-sponsored groups, individual marketplace plans, and some Medicaid managed care arrangements. Anthem Missouri has a medical policy for Spravato that follows Anthem’s national clinical coverage guidelines, with local plan variations.
Anthem’s Spravato coverage in Missouri typically requires:
- Prior authorization before the first dose
- A confirmed diagnosis of treatment-resistant depression (F33.2) or major depressive disorder with acute suicidal ideation (F32.9)
- Documentation that the patient has tried and failed at least two antidepressant medications of adequate dose and duration
- Prescription from a psychiatrist or other qualified provider
- Administration at a REMS-certified facility
Anthem members should call the member services number on their insurance card and ask specifically about Spravato coverage under their specific plan. Individual marketplace plans, large employer group plans, and small group plans may have different benefit structures even within Anthem Missouri.
Other Commercial Payers in Missouri
UnitedHealthcare Missouri covers Spravato subject to prior authorization. UHC’s clinical coverage policies generally align with the FDA label and require documentation of treatment-resistant depression and prior treatment failure.
Cigna Missouri maintains a medical policy for Spravato that follows Cigna’s national guidelines, with prior authorization and clinical criteria documentation required.
Cox Health Plans, a regional insurer based in Springfield, serves a significant portion of southwest Missouri. Members should contact Cox Health Plans directly to confirm Spravato coverage and prior authorization requirements, as regional plan policies can differ from national carrier policies.
Aetna Missouri follows Aetna’s national Spravato medical policy, requiring prior authorization and clinical criteria documentation consistent with the FDA indication.
Step-by-Step Prior Authorization Guidance for Missouri Patients
Here is a practical sequence for pursuing Spravato coverage through any Missouri insurer:
Step 1: Confirm the diagnosis and documentation. Your psychiatrist or prescribing clinician should have a clear clinical record establishing your diagnosis (F33.2 or F32.9), the names and doses of at least two prior antidepressants you have tried, the duration of each trial, and the outcome. This documentation is the foundation of your prior authorization.
Step 2: Identify the correct authorization channel. Your clinic’s billing team will submit the prior authorization. Make sure they know which insurer and plan you have, as submission portals and requirements vary.
Step 3: Request a Letter of Medical Necessity. Ask your prescribing clinician to write a detailed Letter of Medical Necessity that explains your clinical history, why Spravato is indicated, and why other treatments have been insufficient. This letter is often the difference between an approval and a denial.
Step 4: Follow up on the authorization status. Prior authorization timelines vary. Urgent requests may be processed faster if your clinician documents clinical urgency.
Step 5: Request a peer-to-peer review if denied. An initial denial is not a final answer. A peer-to-peer review — where your clinician speaks directly with the insurer’s medical director — reverses a significant proportion of initial denials for Spravato. Ask your clinic whether they routinely request peer-to-peer reviews.
Step 6: File a formal appeal. If peer-to-peer does not resolve the denial, file a formal written appeal. Include all prior documentation plus any additional clinical notes. Missouri’s insurance regulations give you the right to both an internal appeal and, ultimately, an independent external review.
A Note on Cost-Sharing
Even when Spravato is covered, patients typically owe copays or coinsurance. Depending on your Missouri plan’s deductible and out-of-pocket maximum, early sessions in the calendar year may require significant cost-sharing before insurance begins paying in full. Janssen, Spravato’s manufacturer, has offered a patient assistance program for eligible patients; ask your provider’s billing team for details.
For Missouri patients whose insurance denies Spravato coverage entirely and for whom IV ketamine is the only accessible option, the out-of-pocket cost varies by clinic and infusion count. Ask for an itemized quote before committing.
This content is for educational purposes only and does not constitute medical advice. Consult a licensed clinician about your specific situation.
Drafted by AI and reviewed by our editorial team. Last updated 2026-05-30.